Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Clinical Research Fellow at Dana-Farber Cancer Institute, Visiting Professor at McGill University, shared a post on X by Tumor Board Tuesday, adding:
“Adjuvant CDK4/6 inhibitors have truly reshaped the way we treat the most common type of breast cancer (ER+/HER2-). Many open questions remain, though.
Elia Seguí and I will try to tackle them tomorrow evening, at the Tumor Board Tuesday. Make sure to join!”
Quoting Tumor Board Tuesday’s post:
“Starting off 2026, looking to the future of the management of curable breast cancer – and a focus on CDK4/6 Inhibition for HR+ disease:
- Where Are We
- What’s Next
Join us Tuesday, 01-06-26 at 8 PM ET as Paolo Tarantino and Elia Seguí speak on the use of CDK4/6 in early-stage, high-risk Breast Cancer
RT and bring others into the discussion.
And while we finalize the case details, collect FREE CME.”
More posts featuring Paolo Tarantino.